Abstract:From December 2022 to January 2023, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections caused by BA.5 and BF.7 subvariants of B.1.1.529 (Omicron) swept across mainland China. It is crucial to estimate the protective effect of the neutralizing antibodies generated by such mass infections against the next potential SARS-CoV-2 reinfection wave, especially if driven by CH.1.1 or XBB.1.5. Previously, we recruited and continuously followed a cohort of individuals that experienced Omicron BA.1, BA.2, and BA.5 breakthrough infections, as well as a control cohort with no history of SARS-CoV-2 infection. In the previously uninfected cohort, the total symptomatic infection rate surveyed during the outbreak was 91.6%, while the symptomatic reinfection rate was 32.9%, 10.5%, and 2.8% among individuals with prior Omicron BA.1, BA.2 and BA.5 infection, respectively, with median intervals between infections of 335, 225 and 94 days. Pseudovirus neutralization assays were performed in plasma samples collected from previously Omicron BA.1-infected individuals approximately 3 months before the outbreak. Results indicate a robust correlation between the plasma neutralizing antibody titers and the protective effect against symptomatic reinfection. The geometric mean of the 50% neutralizing titers (NT50) against D614G, BA.5, and BF.7 were 2.0, 2.5, and 2.3-fold higher in individuals without symptomatic reinfection than in those with symptomatic reinfection ( p < 0.01). Low plasma neutralizing antibody titer (below the geometric mean of NT50) was associated with an enhanced cumulative risk of symptomatic reinfection, with a hazard ratio (HR) of 23.55 (95% CI: 9.23-60.06) against BF.7 subvariant. Importantly, neutralizing antibodies titers post one month after BF.7/BA.5 breakthrough infections against CH.1.1 and XBB.1.5 are similar to that against BF.7 from individuals with prior BA.1 infection while not experiencing a symptomatic BF.7/BA.5 reinfection (plasma collected 3 months before the outbreak), suggesting that the humoral immunity generated by the current BF.7/BA.5 breakthrough infection may provide protection against CH.1.1 and XBB.1.5 symptomatic reinfection wave for 4 months. Of note, the higher hACE2 binding of XBB.1.5 may reduce the protection period since the potential increase of infectivity. ### Competing Interest Statement Y.C. are co-founders of Singlomics Biopharmaceuticals and inventors of patents associated with SARS-CoV-2 neutralizing antibodies. All other authors declare no competing interests.

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1

Long-term Variations and Potency of Neutralizing Antibodies Against Omicron Subvariants after CoronaVac-inactivated Booster: A 7-Month Follow-Up Study.

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera

Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Neutralization of SARS-CoV-2 BQ.1.1 and XBB.1.5 by Breakthrough Infection Sera from Previous and Current Waves in China

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination

Low neutralization of SARS‐CoV‐2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster

Protective Effect of Plasma Neutralization from Prior SARS-CoV-2 Omicron Infection Against BA.5 Subvariant Symptomatic Reinfection

Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages

Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages

Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients

Changes in Serum-Neutralizing Antibody Potency and Breadth Post-Sars-cov-2 Mrna Vaccine Boost.

Repeated Omicron Infection Dampens Immune Imprinting from Vaccination and Induces Broad Neutralizing Profiles Against Other Omicron Sub-Variants

Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection

Neutralization of SARS-CoV-2 Omicron Sub-lineages BA.1, BA.1.1, and BA.2